Arexvy RSV Vaccine: Guide For Adults 60+ And At-Risk 50-59

The Arexvy vaccine represents a significant advancement in preventing respiratory syncytial virus (RSV) infections, particularly lower respiratory tract disease (LRTD) in older adults. Approved for individuals aged 60 years and older, and selectively for those 50-59 at heightened risk, this vaccine offers robust protection during peak RSV seasons.

Understanding RSV and Its Impact on Older Adults

Respiratory syncytial virus is a highly contagious pathogen that primarily affects the lungs and airways, leading to conditions like bronchiolitis and pneumonia. In New Zealand, RSV peaks during winter and spring months, from April to August, spreading via respiratory droplets from coughs or sneezes. While commonly associated with infants, RSV poses a serious threat to seniors, causing severe LRTD that can result in hospitalization or worse.

For adults over 60, RSV LRTD risk escalates due to age-related immune decline and comorbidities. Clinical data highlight that unvaccinated older adults face substantial illness burdens, with efficacy trials demonstrating Arexvy’s role in mitigating this. Unlike milder infections, severe RSV cases in this demographic often require medical intervention, underscoring the vaccine’s public health value.

Who Qualifies for Arexvy Vaccination?

Primary eligibility targets adults 60 years and older seeking prevention of RSV-associated LRTD. Extended access applies to those aged 50-59 with elevated risks, including chronic conditions or socioeconomic factors.

• Adults 60+: Universal recommendation, especially frail individuals, those in residential care, immunocompromised, or of Māori/Pacific ethnicity in high-deprivation areas.
• Adults 50-59 at risk: Conditions such as asthma, diabetes, COPD, heart failure, or liver/kidney disease.

Consult healthcare providers to assess personal risk. Vaccination history or prior RSV exposure does not preclude benefits, as reinfections remain possible.

How Arexvy Works: Mechanism and Formulation

Arexvy is a recombinant subunit vaccine comprising RSV prefusion F protein and an adjuvant (AS01E) to enhance immune response. It stimulates antibodies targeting the virus’s fusion protein, preventing cell entry and replication.

The product mixes a white powder with an opalescent suspension for a 0.5 mL intramuscular dose, preferably in the deltoid muscle. Unlike live vaccines, its non-live nature suits immunocompromised patients.

Proven Efficacy from Clinical Trials

Arexvy’s effectiveness stems from large-scale trials like the pivotal study involving nearly 25,000 adults 60+. Key results include:

Data show consistent protection across RSV A and B subtypes (84.6% and 80.9%, respectively), with sustained efficacy in high-risk subgroups like those 70+ (84.4%). Severe cases dropped markedly, with 78.8% efficacy over time.

Co-administration with influenza vaccines maintained immunogenicity, supporting combined use during flu season.

Administration Guidelines and Timing

A single 0.5 mL dose suffices, with protection lasting at least two RSV seasons; revaccination needs remain unestablished. Optimal timing precedes New Zealand’s RSV peak (April-August), ideally in autumn.

Intramuscular injection is standard; postpone only for acute severe febrile illness, not minor ailments like colds. It pairs safely with influenza or National Immunisation Schedule vaccines.

Healthcare providers or trained pharmacists (for 60+) administer it. Not licensed for pregnancy.

Potential Side Effects and Safety Profile

Most reactions are mild and transient. Common local effects include injection-site pain, redness, and swelling; systemic ones feature fatigue, headache, myalgia, and fever.

• Frequent (>10%): Solicited reactions resolve within days.
• Rare: Guillain-Barré syndrome observed post-vaccination, but causality unproven; monitor and report adverse events.

Trials reported no excess severe RSV risks; protective responses vary individually.

Availability and Cost in New Zealand

Unfunded by Pharmac, Arexvy requires private payment, with costs around $400-$475 plus administration fees (~$20-$425 total in 2024 offers). Prices fluctuate; verify with providers via Healthpoint directories.

Prepayment may apply for stock ordering. Enrolled patients at clinics like OneHealth can confirm eligibility via email.

Comparing Arexvy to Other RSV Options

Arexvy focuses on active immunization for seniors, contrasting passive options like palivizumab.

Frequently Asked Questions (FAQs)

Can I get Arexvy if I’ve had RSV before?

Yes, prior infection does not confer lasting immunity; vaccination prevents future severe disease.

Is Arexvy safe with other vaccines?

Yes, co-administration with flu shots is supported by trial data.

How long does protection last?

At least two seasons based on 17.8-month follow-up; boosters not yet recommended.

Who can administer it?

Doctors, nurses, or trained pharmacists for 60+.

Is it free in New Zealand?

No, fully private; expect $400+ out-of-pocket.

Consulting Your Healthcare Provider

Discuss Arexvy with your doctor to weigh benefits against risks, especially with comorbidities. Early vaccination maximizes seasonal protection.

This guide synthesizes official data for informed decisions. Report side effects to enhance safety monitoring.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb